Evaluation of a novel device for monitoring of asthma status in symptomatic patients when treated for one month with inhaled corticosteroids.

Redecol Limited0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1. Male or female patients aged 18 to 80 years
•2. Steroid naÃ¯ve patients (not taken steroids for 28 days)
•3. Patients presenting to the chest clinic
•4. Patients able to read and understand the Patient Information Leaflet and Consent Form.
•5. Patients able to provide deep inhaled breaths and exhale while holding a tube in their mouth.
•6. Patients who will be available for subsequent diagnostic tests to be conducted within 30 days of the first visit to the chest clinic.
•7. Patients with a normal Chest X-Ray

•1. Patients who have taken steroid medication in the previous 28 days.
•2. Patients with chest infection or other known lung disease in the previous one month.
•3. Patients who have taken a short-acting beta 2-agonists in the previous 8 hours, (before baseline test).
•4.Patients who have taken Ipratropium bromide in the previous 24 hours, (before baseline test).
•5.Patients with no clinically significant haematology, biochemistry or urinalysis results, (before baseline test).
•6. Patients who have taken Long-acting beta 2-agonists in the previous 24 hours, (before baseline test).
•7. Patients who have taken leukotriene antagonist in the previous 28 days, (before baseline test).
•8. Patients who are too unwell to participate in this study e.g. emergency patients, (before baseline test).
•9.Participants who, in the opinion of the Investigator, will not be able to participate in the study.

发起方

Redecol Limited